Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Deubiquitinase Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for USP28 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | USP28 Wild-Type / C171A Catalytic Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli / Insect cell expressed. |
View USP28 Products |
| Gene Delivery | USP28 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View USP28 Products |
| Benchmark Ab | Anti-USP28 Recombinant Antibody Recombinant positive control for Western Blot, IP, and ELISA validation. |
View USP28 Products |
| Validator | USP28 siRNA Set For target knockdown verification and phenotypic assay validation. |
View USP28 Products |
| Related Target A | USP25 Highly homologous subfamily member (70%+ identity). Essential counter-screening target to ensure drug selectivity. |
View USP25 Products |
| Related Target B | MYC Key downstream oncogenic substrate stabilized by USP28. Crucial readout for functional validation of USP28 inhibitors. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (USP25 vs. USP28 selectivity) | High-purity USP25 and USP28 proteins strictly verified by Mass Spectrometry for structural integrity. |
| Assay noise from bacterial endotoxins in enzyme assays | Strictly controlled endotoxin levels (<1.0 EU/μg) protecting enzymatic assay readouts. |
| Lack of Controls | Highly characterized catalytic inactive mutant (C171A) available as a negative control. |
| False Positives | Sequence-verified siRNA sets included for orthogonal target validation. |
Live USP28 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for USP28 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum deubiquitinase (DUB) inhibitors to highly selective small molecule inhibitors. As first-generation USP25/28 dual inhibitors reach advanced preclinical testing, the next wave of R&D is targeting isoform-specific pocket exploitation to avoid systemic toxicities associated with off-target DUB inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Mission Therapeutics, Ubiquigent, Vicinitas Therapeutics | Colorectal Cancer, NSCLC, Squamous Cell Carcinoma | Selectivity Assay (Need high-purity WT USP28 vs. USP25 panel) |
| PROTAC / DUBTACs | Arvinas, Vicinitas Therapeutics | Solid Tumors (c-Myc driven) | Ternary Complex Validation (Need stable, sequence-verified USP28 proteins) |
| Gene Therapy / RNAi | Academic Institutes, Biotech Startups | Refractory Tumors | Knockdown Verification (Need high-specificity siRNA and Lentivirus) |